1. Panel Discussion: The Recommendations 

Watch back on the recording of the engaging Panel Discussion that took place during The Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Global Summit. 

Susanne Munksted, Chief Precision Officer, Diaceutics

- Dr. Kamala Maddali, President, Health Collaborations LLC

- Dr. Pranil Chandra, Snr VP and Chief Genomics Officer, Pathgroup 

- Cecilia Schott, VP Precision Medicine Portfolio Planning, GSK

*Chair of the Board, Precision Cancer Consortium 

- Dawn Cardeiro, Director of Precision Medicine, Point32Health

- Dr. Daryl Pritchard, Snr VP of Science Policy, Personalized Medicine Coalition

- Brenda Yanak, Founder, Clinical Transformation Partners

- Sarah Hersey, VP Head of Precision Medicine, Bristol Myers Squibb

- Prof. Mark Lawler, Chair in Translational Cancer Genomics, Queen's University Belfast. 

Economic Summit Recording: Forum Members Panel Discussion, The Recommendations

Watch our engaging Q&A session hosted by Denny Van Liew taking questions from the audience and online. 

Economic Summit Recordings: Q&A

 concluded the Summit with a fireside chat with Diaceutics Founder 

, which sparked a lively discussion on the evolution of our healthcare and life sciences ecosystem.

Watch the full recording of this session below: 

Economic Summit Recording: Fireside Chat

Watch back on the recordings of The Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Global Summit. 

Follow the link to log on or register and access the full document with all of the links to the chosen papers and articles. 

As part of the Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Global Summit we have collated an additional set of papers and articles that introduce the micro and macro economic assessments completed to date on precision medicine and in particular precision testing. 

Follow the link and log on or register to access the full document with all of the links to the chosen papers and articles. 

As part of the Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Global Summit we have collated an initial set of papers and articles that introduce the micro and macro economic assessments completed to date on precision medicine and in particular precision testing. 

64.4% of lung cancer patients in the US do not receive the right treatment for them. 

There are 7 “gaps” in which patients are being lost in their testing journey

18% of patients do not receive treatment due to inconclusive or false negative diagnostic results 

29% of patients were also lost due to a gap in clinicians not prescribing the targeted or immuno-oncology therapy the patient could have benefitted from despite the diagnostics being carried out correctly. 

There exists a huge opportunity for stakeholders within the precision medicine industry to take action and enable patients to receive the treatment they deserve

Log on or register to download the paper 

'The Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer.'

Our latest in-depth study carried out in conjunction with the Personalized Medicine Coalition regarding the use of diagnostic testing for lung cancer patients in the US identified that over half of patients are not receiving the right treatment for them.

Helen Sadik, Daryl Pritchard, Derry-Mae Keeling, Frank Policht, Peter Riccelli, Gretta Stone, Kira Finkel, Jeff Schreier, and Susanne Munksted. JCO Precision Oncology 2022:6

 provides a birds-eye-view highlighting issues within the diagnostic ecosystem that are impeding patient access to precision medicine.

uses NSCLC in the as a disease-level sandbox to illustrative the flaws in the current diagnostic ecosystem.

The latest Precision Medicine Readiness Report 

reviews the key forces reshaping the precision medicine landscape and looks toward a new era of patient testing, that unites all stakeholders.

The Axis for Change Series Download

All three parts of the Axis for Change series are available for download and read now. 

Raymond Henderson, Declan French, Elaine Stewart, Dave Smart, Adam Idica, Sandra Redmond, Markus Eckstein, Jordan Clark, Richard Sullivan, Peter Keeling, Mark Lawler

Precision medicine drugs cost $1bn less to develop than traditional drugs, mainly due to smaller clinical trials and the accelerated path to the market

Historically precision medicine sales have averaged $5.2bn over the lifetime of the drug, considerably less than non-precision medicine oncology therapies

The authors note that the precision medicine revenues are significantly constrained because of inefficiencies in the diagnostic pathway denying the drugs access to 64% of potentially eligible patients

Recommendations include moving towards a precision oncology CDx-guided approach which can deliver health benefits at a potentially affordable cost, including in the development phase, lowering expensive clinical trial attrition rates, and sparing unselected patients those treatments that are ineffective and may have significant side effects

We are delighted to see the publication in the Journal of Pharmaceutical Policy and Practice of the first definitive benchmark financial analysis of precision medicine vs OSFA oncology therapies. We believe this baseline landmark work will have multiple benefits to the precision medicine community and support economic value, pricing and investment analysis. 

Insights

Economic Summit Recording: Forum Members Panel Discussion, The Recommendations

The Evidence Suite Volume 2

The Evidence Suite Volume 1

Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small Cell Lung Cancer

The Axis for Change series of Reports

Delivering the Precision Oncology Paradigm